John Gonzalez, Chairman
Dr Gonzalez joined Endomag from Alice Ventures (Italy, UK) where he was the Life Sciences Partner from 1999. Prior to his successful investment career with Alice Ventures, he was in charge of European business development for both PowderJect Pharmaceuticals and SmithKline Beecham. He holds an MBA from the London Business School and a Bachelor of Medicine and Bachelor of Surgery from the University of Manchester.
Eric Mayes, CEO
Dr Mayes has over 15 years’ experience in developing and leading materials technology companies. Prior to joining Endomag as CEO in 2010, Eric held executive positions in Cambridge Display Technology (CDT) and NanoMagnetics. He was named the Royal Society of Chemistry’s ‘Entrepreneur of the Year 2003’ for his founding role in NanoMagnetics. Eric is an advisor to the University of Texas at Austin’s ‘Texas Health Catalyst’ and the European Nanomedicine Translation Advisory Board (TAB). A US-UK dual national, he holds a BSc in Physics from Arkansas State University and a PhD in Chemistry from the University of Bath. Eric is a Fellow of the Royal Society of Chemistry.
John has been a venture partner at Sussex Place Ventures since returning from the US in 2005 where he was COO of Hands-On Mobile, a major venture-backed mobile content delivery technology and publishing business with worldwide operations. He is also Chairman of Linguamatics, a provider of advanced knowledge discovery tools to the pharmaceuticals sector. John previously founded Jobstream Group Plc, a software business serving the institutional offshore finance market. John has an MA in Law and Diploma in computer science from Trinity College, Cambridge.
Dr George was appointed CSO of New Wave Ventures in October 2013, having previously served as a member of its Advisory Board. He is a non-executive director of several portfolio companies including Discuva, Cambridge Scientific Innovations, Regenerys and Endomag. Ian co-founded Enigma Diagnostics and led its business development activities, and has a significant background in technology commercialisation including roles with TTP, the Defence Science Technology Laboratory and Unilever. Ian holds a first class BSc from Cardiff University and a PhD from the Roslin Institute, Edinburgh.
Peter is a chartered accountant with over 30 years’ experience in the management and growth of life science and technology companies, both as an executive and investor. In 1992, he was a co-founder and finance director of Chiroscience Group plc, leading its initial public offering in 1994. In 1996, he co-founded the venture capital firm Merlin Biosciences and was responsible for many early-stage healthcare investments. In 2013, he was the founder chief executive of Cambridge Innovation Capital plc, an investment fund established to support technology businesses from the University of Cambridge or located within the Cambridge cluster. He is an experienced non-executive director, holding board positions on numerous private and public companies including Abcam, Horizon Discovery, Arakis and Vectura.
Dr Schooling is Director of Engineering & Physical Sciences at UCL Business and is responsible for knowledge transfer activities across the faculties of Engineering, Mathematics and Physical Science and the Built Environment at UCL. He has significant experience of early-stage technology commercialisation within a research-led university, having developed successful spin-off companies and executed licensing agreements in sectors ranging from telecommunications through to oil and gas and medical imaging. He is currently a director of six UCL spin-out companies and represents UCL’s interests in an IT-focused seed stage investment fund.